8-K: Disc Medicine Announces Positive Topline Results from Phase 2 AURORA Study of Bitopertin for EPP

Disc Medicine's Phase 2 AURORA study of bitopertin in EPP patients showed statistically significant reductions in protoporphyrin IX (PPIX) and improvements in phototoxic reactions and patient global impression of change.

Summary

• Disc Medicine reported topline results from its Phase 2 AURORA study of bitopertin in patients with Erythropoietic Protoporphyria (EPP).
• The study met its primary endpoint, demonstrating statistically significant, dose-dependent reductions in protoporphyrin IX (PPIX) levels.
• The 20 mg dose of bitopertin resulted in a 21.6% reduction in PPIX levels (p=0.003 vs placebo), while the 60 mg dose resulted in a 40.7% reduction (p<0.001 vs placebo).
• The placebo group showed an 8.0% increase in PPIX levels.
• Bitopertin also showed significant improvements in the rate of phototoxic reactions with pain, with a 75% reduction at the 60 mg dose (p=0.011) and a 60% reduction at the 20 mg dose (p=0.109).
• Fewer bitopertin-treated patients reported a phototoxic event compared to placebo, with 19% in the 20 mg group and 12% in the 60 mg group, compared to 46% in the placebo group.
• The study also showed dose-dependent improvements in Patient Global Impression of Change (PGIC), with 86% of completers at 60 mg and 77% at 20 mg reporting much better EPP compared to 50% for placebo (p=0.022 for 60mg).
• While bitopertin-treated patients showed a positive response in cumulative time in sunlight, this secondary endpoint did not reach statistical significance due to a strong placebo response.
• Bitopertin was generally well-tolerated, with no serious adverse events and stable hemoglobin levels.

Sentiment

Score: 8

Explanation: The document presents positive topline results from a Phase 2 study, with statistically significant improvements in key endpoints. While there are some challenges with a secondary endpoint, the overall tone is optimistic and suggests potential for future development.

Positives

• Bitopertin demonstrated significant, dose-dependent reductions in PPIX levels, the primary endpoint of the study.
• The study showed substantial reductions in phototoxic reactions with pain, particularly at the 60 mg dose.
• Patients treated with bitopertin reported significant improvements in their overall condition, as measured by the Patient Global Impression of Change.
• Bitopertin was generally well-tolerated with no serious adverse events and stable hemoglobin levels.

Negatives

• The key secondary endpoint of cumulative time in sunlight did not reach statistical significance due to a strong placebo response.
• Two patients in the 60 mg dose group discontinued treatment due to treatment-emergent adverse events.

Risks

• The strong placebo response in the cumulative time in sunlight endpoint may complicate the definition of optimal registrational endpoints.
• The company will need to conduct further analysis and work with regulators to determine the best path forward.
• The forward-looking statements are subject to risks and uncertainties, including the success of future clinical trials and regulatory approvals.

Future Outlook

The company is planning to analyze the final data set and work with investigators, regulators, and patient advocacy groups to define the optimal registrational endpoints moving forward. They are also anticipating updated data from their DISC-0974 study in anemia of myelofibrosis in Q2.

Management Comments

• John Quisel, J.D., Ph.D., President and Chief Executive Officer, stated that the study confirmed bitopertin significantly reduces the toxic metabolite, PPIX, in patients with EPP.
• He also noted that bitopertin-treated patients experienced improvements in clinically meaningful outcomes, such as Patient Global Impression of Change and the number and rate of phototoxic reactions with pain.
• Quisel mentioned that the statistical significance for the key secondary endpoint of cumulative time in light was not met due to an outsized placebo response.

Industry Context

This announcement is significant for the EPP treatment landscape, as there is currently only one FDA-approved therapy, Scenesse, which is a surgically implanted synthetic hormone. Bitopertin, if approved, could offer a new treatment option for patients with EPP, potentially as a first disease-modifying therapy.

Comparison to Industry Standards

• The results of the AURORA study are being compared to the BEACON study, another trial of bitopertin in EPP patients.
• The reduction in PPIX levels is a key metric in EPP treatment, and the results of the AURORA study show a significant improvement compared to placebo.
• The improvement in phototoxic reactions and PGIC are also important clinical outcomes that are being evaluated in the context of existing treatments and other clinical trials in EPP.

Stakeholder Impact

• Shareholders may react positively to the positive topline results.
• Patients with EPP may benefit from a potential new treatment option.
• The company's employees may be motivated by the progress of the clinical trial.

Next Steps

• The company will analyze the final data set from the AURORA study.
• They will work with investigators, regulators, and patient advocacy groups to define optimal registrational endpoints.
• The company anticipates updated data from their DISC-0974 study in anemia of myelofibrosis in Q2.

Key Dates

Keywords

Bitopertin, Erythropoietic Protoporphyria, EPP, PPIX, Phase 2, AURORA Study, Hematologic Diseases, Phototoxic Reactions, Clinical Trial, Disc Medicine